Novo's Phase 3 CagriSema results disappoint analysts, sending stock tumbling MM+M Medical Marketing and Media Novo Nordisk: Can CagriSema Show 25% Weight Loss In REDEFINE 1 Trial? Seeking Alpha Incretin based therapies for the treatment of obesity related diseases npj Metabolic Health and Disease Zepbound Outperforms CagriSema in Head to Head Phase III Obesity Trial CagriSema drives weight loss in rats by reducing energy intake and preserving energy expenditure Nature Metabolism Cagrilintide (AM833) Long acting amylin analog. Beta cells make TWO hormones: insulin and amylin. Amylin slows stomach emptying and reduces appetite. Cagrilintide is a long acting synthetic amylin designed for once weekly dosing